$1.24
0.00% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US4495851085
Symbol
IGMS
Sector
Industry

IGM Biosciences Inc Stock price

$1.24
-0.04 3.13% 1M
-8.53 87.30% 6M
-4.87 79.71% YTD
-7.13 85.19% 1Y
-16.27 92.92% 3Y
-56.60 97.86% 5Y
-23.06 94.90% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.00 0.00%
ISIN
US4495851085
Symbol
IGMS
Sector
Industry

Key metrics

Market capitalization $74.54m
Enterprise Value $-33.61m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.23
EV/Sales (TTM) EV/Sales -12.54
P/S ratio (TTM) P/S ratio 27.81
P/B ratio (TTM) P/B ratio 106.71
Revenue growth (TTM) Revenue growth 27.36%
Revenue (TTM) Revenue $2.68m
EBIT (operating result TTM) EBIT $-171.55m
Free Cash Flow (TTM) Free Cash Flow $-146.50m
Cash position $152.11m
EPS (TTM) EPS $-3.28
P/E forward negative
P/S forward 11.04
EV/Sales forward negative
Short interest 4.48%
Show more

Is IGM Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

IGM Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a IGM Biosciences Inc forecast:

2x Hold
50%
2x Sell
50%

Analyst Opinions

4 Analysts have issued a IGM Biosciences Inc forecast:

Hold
50%
Sell
50%

Financial data from IGM Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2.68 2.68
27% 27%
100%
- Direct Costs 9.21 9.21
9% 9%
344%
-6.53 -6.53
19% 19%
-244%
- Selling and Administrative Expenses 33 33
9% 9%
1,229%
- Research and Development Expense 123 123
38% 38%
4,585%
-162 -162
33% 33%
-6,057%
- Depreciation and Amortization 9.21 9.21
9% 9%
344%
EBIT (Operating Income) EBIT -172 -172
32% 32%
-6,401%
Net Profit -199 -199
16% 16%
-7,421%

In millions USD.

Don't miss a Thing! We will send you all news about IGM Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IGM Biosciences Inc Stock News

Negative
Market Watch
4 months ago
IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.
Neutral
GlobeNewsWire
4 months ago
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patient...

Company Profile

IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firms product pipe line includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies; IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies; and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Head office United States
CEO Mary Harler
Employees 149
Founded 2010
Website www.igmbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today